STTK - Earnings call transcript Q2 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, everyone, and welcome to Shattuck Labs Second Quarter Financial Results and Business Updates Call. Today’s call is being recorded. At this time, I would like to turn the call over to Conor Richardson, Senior Director of Finance and Investor Relations of Shattuck Labs.

Conor Richardson

Thank you, operator. Good afternoon, everyone, and welcome to the Shattuck Labs conference call to discuss our second quarter financial results and business updates. website our and was the can Presentation of for close after Events release section afternoon this be our press financial issued results market and The shattucklabs.com. found on

Shattuck Q&A During this of second our session for our will of quarter SL-XXXXXX will to remarks. a including update development business follow the an team XXXX, clinical afternoon’s overview provide and the call, plans SL-XXXXXX. prepared A

our Officer; Chief are today Officer; Dr. Schreiber, Dr. call Lini Chief the Executive Pandite, Business Officer. our Casi on me Neill, Joining and DeYoung, Medical Chief our Andrew Taylor Officer; Chief Financial our

Before implied XXXX. from within remind these that you the expressed Such to judgment as statements begin, Litigation and of that statements Safe would results differ of materially Securities forward-looking provisions represent involve uncertainties Harbor management’s contains we by and like today, certain risks meaning the could or of I of today’s may actual Act to cause those Private webcast Reform in statements.

forward-looking on information uncertainties, SEC, the Form our on Executive Officer. recent that, year August Taylor? SEC’s website these and website Taylor of Chief more our are turn to Schreiber, will and the other from For statements which to filings ended our represent on available for the our with Annual the XX-K XX, as shattucklabs.com. please now most XX, or views Any XXXX, Report I refer our With corporate today, XXXX. call December over risks

Taylor Schreiber

I October and since and am initial the Today’s call first earnings Good XXXX our proud Thank us. of everyone, in is offering afternoon, thank you exceptionally you, joining for milestones. Conor. public the of

time. achieved has since Our that team

SL-XXXXXX clinical job has of done the SL-XXXXXX compounds. Checkpoint an stage our clinical and advancing or development of ARC Redirected team Our outstanding clinical Agonist both

cell with and the bi-functional another skin. squamous SIRPα-Fc-CDXXL neck a patients for is one carcinoma patients with for of different head clinical in XXXXXX two protein fusion ovarian reminder, a cancer advanced Phase X currently trials, As and or

candidates clinical Takeda second tumors. stage PDX-Fc-OXXXL compound with X bi-functional collaboration is Both a and the founding with of fusion of clinic four work in Pharmaceuticals patients the our manufacturing XXXXXX Phase our than to our due years protein regulatory in scientific are that solid for ARC Our entered pioneering is advanced since in teams. first-in-class compounds being developed development product less and

with the We platform. the validate few And are to generating are just time. a excited to concept particularly progress currently ARC data you clinical months we share this behind in clinical

our portion clinical for on have at we Immunotherapy monotherapy trials X Specifically, submitted November Emerging SITC as expand data of and general XXXXXX expansions context the to to meeting escalation we annual clinical our also its for from data XXXXXX of presentation will our clinical Phase today, those and for for through provide amend dose the known guided some Cancer And addition us trials. in update. corporate our XX. Society has XX to

dose relapsed/refractory During made XXXXXX advancing XXXX, towards with for steady patients in the escalation ovarian we’ve cohorts progress cancer.

escalate dose by to thus cohorts. and the dose and into pleased observed are profile are safety the tolerability far We higher continuing level

we the hematologic into the date, clinical broaden data of totality have to development execute Given strategy to our malignancies. to on begun

We patients TPXX as a including initiate to a compound myeloid acute with leukemia, XXXXXX clinical for for patient for potentially an well for these mutant patients as myeloid trial as risk see soon cohort, emerge higher will we populations. with a leukemia syndrome. opportunity Specifically, acute best-in-class myelodysplastic

XXXXXX. for have our clinical development made significant We in also efforts progress

with ARC regarding which available in the through Lini behavior level compounds the data dose per for We kilogram escalation moments. contemplated enormous dose per on patients our a completed cancer. beyond weekly expand both top evaluated of dose enrollment continued rationale scientific schedules will originally X kilogram, compelling, and in gained there suggests that milligram X is few a level and dosing milligrams of The have bi-weekly insights

update. Technical technical large Officer. leadership Lini? plan the pleasure quarter team. companies. a turn advantage manufacturing programs has to our biotechnology from Dr. my XXXX. as this the update corporate a brings to to that, clinical pharmaceutical Lini our biologics later Medical Pandite, of our growing well biologics Abhinav wealth Lini Then held for to will in concluding very Andrew our second Officer. I experience we joined our to Chief provide call build to He of at pleased It and we to will greater insights to Turning now is discuss the companies, the roles for development am strategy. platform, our of date. executive manufacturing I’ll and be will introduce our capabilities. detail then has team. Abhinav comments. And is Abhinav back both continue our Today’s internal full experience who contract Chief organizations, which as discuss across at financial small welcome Shukla into our manufacturing I select data critical Abhinav spectrum quarter as as unveiling ARC over some clinical With SITC year, on call we’ll clinical us this

Lini Pandite

Thank Taylor, and afternoon, you, good everyone.

a our protein. discuss programs First, fusion clinical lead would bi-functional SL-XXXXXX, is I SIRPα-Fc-CDXXL like to which

cellular binds domain CDXX. and As SIRPα which protein, of to the directly SL-XXXXXX contains extra reminder, a inhibits the human

ligand contains receptor. the In also CDXX to the extra directly cellular and addition, domain activate of the SL-XXXXXX protein simultaneously human CDXX

clinical you exploring X in As SL-XXXXXX most Phase we currently know, ongoing of two trials. are

tolerability, activity, the Our monotherapy monotherapy of of escalation dose patients SL-XXXXXX cancer. first with progressed relapsed/refractory SL-XXXXXX administration as effects the pharmacodynamic Enrollment smoothly. in has anti-tumor label a cohorts intravenous multicenter of clinical in dose intended ovarian trial is study and escalation safety, assess open to pharmacokinetics,

dose milligrams dose are thereafter. completing We proceed XX currently at to of we to the milligrams kilogram and plan next per X fourth the enrollment level level per of kilogram

and we pleased the toxicities Overall, SL-XXXXXX. in date emerging been dose in we in CDXX profile inhibitors cohorts, are of dose should dose considered relapsed/refractory study half CDXX first pharmacodynamic cell because safety, clinical assess inhibitory context tumor pharmacokinetics level head Our agonists. in to and CDXX remain second clinical ongoing observed data data of To of clinical track with squamous prior of or SL-XXXXXX limiting multi-center XXXX. administration and an And carcinoma the by contains trial. ability to trial We tolerability, SL-XXXXXX and the higher SL-XXXXXX and activity either are both have the be the with from of no escalation study initial to intratumoral of on agonist with is safety very in the dose domains, intended open-label present skin. encouraged as the patients CDXX our monotherapy neck this effects

evidence Fc toxicities that anemia CDXX in agonist but CDXX and dose a with is the of milligram this side, have testing combination we X CDXX toxicities, our over contributes syndrome that have SL-XXXXXX, of to To to and hampered repeatedly thrombocytopenia, encountered major any and evidence from level the date, which worth at of not SITC the of CDXX of later or the the a other inhibitors evidence an curve. Fc preclinical pharmacodynamic In dose safety low the level region of current to On years, doses CDXX antibodies is previously with combination observed further profile we consistent be including one at by studied X.X side, because XXth XX differentiates dysfunction response study, these SL-XXXXXX. or of of kilogram, is per been have activity. roughly per silence bell-shaped and doses observed well reported the active conference SL-XXXXXX domains progress Yet, we would kilogram plan clinical data, believe anemia believe milestone agonist which a the adverse a selection cytokine share due dose been liver case remembering clearing effector have for we it CDXX thrombocytopenia unique release We limiting events. SL-XXXXXX. of has dose milligrams in year. On of about this observed clinical We have for none details engagement

we in emerging prompted SL-XXXXXX to today, our excited azacitidine. malignancies. are the acute combination as myeloid active Phase plan immunologically from in study Xa to entered and hematologic we we not to with AML, an expand of the in trial into cancer and myelodysplastic we MDS, clinical and to believe agonists. plan we well combination And AML, that to in in SL-XXXXXX excited as has are Xa/Xb studies azacitidine venetoclax. that plans profile SL-XXXXXX window, TPXX We emerging mutant the with in clinical us immunologically therapeutic trial ovarian syndrome. high-risk In profile study seen plan encouraged leukemia risk initiate CDXX dose higher announce both clinical In prior an bridge by to and to Phase The of SL-XXXXXX have very active the

file a Phase an for opportunity inhibitors effects IND MDS. differentiate be initiate to have from costimulation. CDXX the and SL-XXXXXX the to fourth XA/B in of Specific an field the clinical demonstrated class for the thereafter. this AML CDXX see compounds activity blockade in higher datas We on CDXX a and to forthcoming, both trial other quarter expect will trial this risk in design as and trial year, We of combined

ligand to Now PDX-Fc-OXXXL to our protein. I turn attention fusion like our would SL-XXXXXX, bi-functional

milligrams PD-X/PD-LX To pretreated the to patients SL-XXXXXX first currently multicenter of Phase solid milligrams six in of two patient evaluate most to are we predominantly population beginning and dosing monotherapy as escalation experienced enrolled lymphoma. you per advanced XX from cohorts a our heavily schedules. date, we dose with minus planned a and X have the level initially dose in X tumors enrolling evaluated trial to As kilogram kilogram, per across know, open-label intravenously administered

limiting We have observed any not highest dose the to level. toxicities dose

forward of response dose additional and OXXX in antitumor we are that Because data a Overall, data of per clinical PD-X cells from reported known dose and rates complete the for levels SL-XXXXXX This look to cohort. beyond SL-XXXXXX has observed respectively PD-X have in non-PD-LX dose not have response experienced expected manner with prior our pharmacodynamic plan antibodies. that per PK, it prior underlying CDXX through the of rapid feasible activity, positive ARC PD-LX XX to two observed our additional future enrolled Officer. effect not to higher levels indicate of were dependent a previously time, that activation Because Thus, now will could to very Neill, with made to profiles forward platform dose unclear progress populations. antibodies. clinical remains Andrew? PD-LX believe the that, we I milligrams and patients additional expressing OXXX and these the OXXX growth milligrams both from our agonist with pleased for in OXXX continue tumors, may of egress more inhibition stage this and engagement agonist dose in the Financial CDXX indicates from to We looking plan and seen a rates with OXXX consistent enable and a been demonstrate be increase with tumors, At is OXXX positive cells the escalate patients our assessment PD pharmacodynamic and efforts. on to the look have however, Chief of to development that is we XX over select Andrew date now date showing product target hypothesis derived. We With we’ll ARC development primary is kilogram. patients. in we T both activation emerging kilogram the circulation, few to receptor path a which which we clinical the candidates turn experienced call what

Andrew Neill

good Lini, afternoon, everyone. and you, Thank

quarter to our in the of from mentioned, our XXXX second forthcoming and are release Today, focus Conor results on few our earnings available key full would disclosures. like XX-Q. a As for financial I press points the

positioned are We financially. to well be fortunate

have revenue cash for of XXXX and ended As million quarter million. quarter and negative ended was investments June in agreement short-term revenue the our second solely negative of $XXX.X costs collaboration the June complete we equivalents generated to-date million compared is the quarter with of to Revenue June $X.X cash XX, second performance approximately XX, increased All XXXX, for required the by Takeda, $X.X expected XXXX second XX, was driven for our collaboration the XXXX. agreement. to from obligations

of to quarter general second second the for XXXX. million and our $X.X to compared second expenses revenue The the As XXXX, affect a development does expenses for the plan million quarter XXXX, $XX.X modifications the result and clinical In our $X.X $X.X the not for second administrative development In were million our position. cash negative of SL-XXXXXX. of research XXXX. our quarter million to were of quarter of compared

Our diluted net and a loss $X.XX for million of share basic compared XXXX $X.XX $X.X or net loss and second basic the for quarter of a the diluted share. second was $XX.X of to million of or per quarter per XXXX loss

and our Now financial to turning guidance beyond. for XXXX

Our offering financial guidance in given in connection with XXXX. from our October unchanged initial guidance remains the public

expansion in internal operations, our our year to change and our included Importantly, current AML back and associated through will patients with end the expected turn operating planned clinical runway guidance, cash because trials our current Based call with XXXX. now of runway on were high-risk SL-XXXXXX does trials not I forecasts. into And over the these MDS cash that, with Taylor. Taylor? remains expenses in

Taylor Schreiber

Andrew. you, Thank

first advanced with to our humans to-date, with well Shattuck platform apply SL-XXXXXX very in Over progress for clinical the has best for and SL-XXXXXX ARC learnings the year, past the have which tremendous been benefit learning ARC the bodes are from two we well a patients how platform the as whole. trials. made cancers of tolerated and

In the to an central and monoclonal the hypotheses compounds linear one believe ARCs observations platform will SL-XXXXXX. engage ARC TNF addition, relationship we We fundamentally the a between of antibodies. to validate manner receptors these of like responses and have different hexameric corresponding that IgG than ARC dose SL-XXXXXX pharmacodynamic in escalating the observed administered

reach that us with identify dose and we to will effects heterogeneous in this proceed the We profile to patient and SL-XXXXXX maximum quickly through in at of highly believe dose been pharmacokinetic began and study characterize allow population the collected additional unselected which the PD-LX the exciting, to stimulation a escalation. progress dose from order fully pharmacodynamic OXXX escalation Our has data cohorts levels.

depend increase experienced now the at it patient enrich PD-X with SL-XXXXXX enormous An are a or we for Now to levels. excited observing a that further of higher inhibitor will however, experience PD-LX these selected positive PD-X tumors. is or clear, It will for dose opportunity range, to a to is and dose stimulation forward what in population. beyond not patients immunologically are And remains unmet characterize PD-X rates within antibody in OXXX and activity in refractory dose at antibody PD-LX whether patients yet monotherapy SL-XXXXXX patients an active is patient in the appropriate need upon population. response expected PD-LX address PD-X PD-LX we higher PD-LX levels path

the years. CDXX high-risk from trial of co-stimulatory encouraged IgG ARC the our the filing with highly also are We whereas data Phase stimulator data suggests over Xa, inhibitor. of ovarian opportunity cancer, escalation That TNF in surrounded IgG class exploration malignancies dose OXXX the of portion CDXX suggest in inhibitors antibody inhibitor. possible the by level XX and modalities clinical dose is of antibody subtle. the dogma and forward of a that fold further immune the of biologic a not levels our that SL-XXXXXX CDXX time. more will receptor believe occupancy a in data with CDXX early OXXX complete receptors consequences the a look system, We into expansion suggesting for to to of that just few agonist at family have stimulation for antibodies, maximum escalation versus has for high hematologic evaded SL-XXXXXX is the our biology a CDXX, Xb agonist MDS that IND for that This with a very effectively clinical also in toxicity of CDXX limiting higher at SL-XXXXXX dose than dose window potential for and SL-XXXXXX the in believe prior from has demonstrate super year. milligrams of the and tolerated patients on CDXX manner per compare quarter effects SL-XXXXXX required range other which We trial said, which based was levels CDXX to in therapies. XX achieve X are gap dose The powerful the Several platform best dose in that bridge a immune a SL-XXXXXX because and is perceived the unlocked some this dose is dosing kilogram, The may to emerging OXXX a decades. as months clinical the a AML has signs targets fourth cleared of limited by has of CDXX activation diminishing higher and challenge We’ll these contrast been combination to toxicity activation. a of began

like and would by clinical half have continued that look this the the progress possible. appraised of progress Shattuck, participated I to patients appreciate throughout Q&A, our have employees who year call From trials to bring. forward and make it this would to for turn all our institutions, the the helped and look investigators, and close I thanking With forward we we your importantly, in and clinical teams their operator, all you their questions. milestones to We in most like Shattuck Before will and families of our interest open of to year. the second the keeping at of

Operator

Our Marc first comes Frahm from question from Instructions] [Operator Cowen.

begin. may You

Ernie Rodriguez

anemia follow-up what Hi, on thank seen occupancy have Ernie just have you regarding progress. Have if question ladle and on what achieved? is Marc. for SL-XXXXXX. commentary a above experienced you have level Shattuck? occupancy a on for CDXX We receptor Congratulations or call. the is And of the receptor that for others you This taking this your discussed Rodriguez the the

Taylor Schreiber

the questions. is Sure. This Taylor. Hi, Ernie, you and thank for

SITC. that will specific receptor be disclosing We at levels occupancy

didn’t an occupancy expressing cells, antibody on see more levels that that levels But occupancy contrast the targeted then to saw with kilogram. early reached into roughly began of other until like red at proteins little expressing antibody occur bit and receptor blood milligrams X different and CDXX of been fusion context to example, the per saturation CDXX a shown a magrolimab achieve XX kilogram. with agents. for and the with been per between has of However, some reported full proteins, with occupancy of levels In leukocytes. things what I mean can SIRPa-Fc full those different put of CDXX milligrams can fusion some X they And have dose Fc

or on the reported cannot of have fusion leukocytes of positive CDXX why proteins leukocytes is some that impression XXX% affinity a lower the than fusion that of not leukocytes reason high on fall not affinity proteins some avidity, you and the SIRPa is a CDXX or occupancy occupancy proteins. XXX% on faster SIRPa-Fc off either off have rate Our fusion faster lower SIRPa-Fc avidity high achieve

hopefully, So a of that provides bit context.

Ernie Rodriguez

Thank helpful. very you. That’s

Operator

from Our next Miller comes Jonathan of from question Evercore the line ISI.

begin. may You

Jonathan Miller

Hi on data. the I And we But to forward responses very has it look clinical far from supportive guys. yet. will taking no my which but programs, Thanks really both that, on safety mean, been question. like, agency, looking forward so significant seems for I’m seeing to what SL-XXXXXX escalation

in to you trials to to you have of as expectations moved planning rate indications, are meaningful what we’re active So or sort that active now immunologically then certainly of you’re a Do the starting we’re obviously dose there. we’re that at as pursue have Competitors combo soon going mono entering key all as that’ll development. further comfortable the we get activity get entering just secondly, direction? as development monotherapy heme to to any activity given biochemical with dose for signals trials, us are range, turn range. combo And robustly

Taylor Schreiber

take Jon. Lini the part of to I’ll first Sure. Thank question and second. the the you, take then

expect and all there and profile of see turn you the to the OXXX the can will at a SL-XXXXXX programs data both your well will And as as MDS. regarding include the dose pharmacodynamic response second compound both with I in as take and across receptor activity. question AML effects is date cytokine of occupancy ask ranges, elaborate levels. lymphocytes, characteristics in as for pharmacokinetic data term to the compounds the various Lini engaging first safety various then to that then the well. dose The and the SITC What OXXX Lini analysis, patient half margination the of And at mentioned should for the of and antitumor dose So my on she compound immunophenotypic positive levels.

Lini Pandite

for you the question. Thank

MDS very very this That’s monotherapy of With to short the plan AML a quickly. into our is portion combination go and the monotherapy.

So bringing we are dose. immunologically active an

bridging venetoclax the plan that And from our that quickly monotherapy, is and are a venetoclax. X with to into We study. dose azacitidine, Phase I go and azacitidine mentioned the it’s combinations with ovarian azacitidine azacitidine,

Jonathan Miller

Okay.

no there’s that developing monotherapy substantial that expectation think there I seeing in of direction… or So activity

Taylor Schreiber

activity FC XX-plus the in quick If have sporadic monotherapy what that, melanoma, known is of expected agents. studies is because clinically of agonist that have pattern is there based least experience shown monotherapy And inhibitor. antitumor activity interpretation Jon, CDXX what to you human agents we CDXX of around don’t And cell some at monotherapy on silent CDXX point. clinical about the upon around things. based as with years mind, well monotherapy feel as carcinoma appropriate we one frame lymphoma, guidance while and tumors CDXX it’s It’s I’ll that, renal about activity that known any agonist expectations efficacy make agonist don’t comment antibodies consistent antibodies. in no our for upon of the like activity, just the expected agonist, CDXX of SL-XXXXXX the clinically the And an our is activity two

lack CDXX the domain. function activity activity which residual have the those On they don’t inventory that only monotherapy do agents have not shown that have CDXX monotherapy Fc agents, the are have that side, also tox. in and function

drive toxicity. tells Fc the of that class CDXX in and domain inhibitors characteristics the the as to you with a Fc themselves of the and that domain what sufficient is are so And

notice registrational either whether pathways targeted are combination Fc certain ADCP-competent you chemotherapies domain inactive, of or they tumor that inhibitors, in However, pursuing is about the is CDXX active or antibodies. regardless what all with all

while then insufficient the sporadic it say can extend Fc to so you for drive monotherapy tox conclusion is registration. and and domain sufficient And a that activity, there the bit is from

Fc this upon being inactive framing SL-XXXXXX with we based are, with so inhibitor a CDXX an agent, expectations again, domain. And

Jonathan Miller

you. Thank Great.

And I the think go clinical of of details Maybe along that’s into periphery there a very bit you the signs little or relevance of T-cell turning SL-XXXXXX, to other pushing stimulation patients, responsible. the trying can to many of on focus that in speak going activation I’m on that? these blood? Are OXXX out tell of access can tough granted, but PD what’s given us and it’s that to the positivity with specifically successful disambiguate lack OXXX about immunostimulation. PD-LX what

Taylor Schreiber

the Yes, Jon. thanks for question,

antigen So dependent specific T-cell co-stimulator. CDX OXXX is an

of hard with little convincing contains way are the of the activated, and And in tissues to forms. expect of the effects And cells OXXX changes so blood other in in the And the of being of of that. come positive you population. see T that cells including out peripheral expect actively if profile some cell tumor experience specifically say you of provide very would those stimulation to a may in that actively then to or That But pharmacodynamic, OXXX cells markers come into subset at could could the date. from immunophenotypic least form tissues, the that because includes pharmacodynamic case this T more rapidly direct sure tumor carry, are if activity and And the OXXX transporting signs cells, for to could in that blood SL-XXXXXX of of you that tissues. a to on encountering to then peripheral CDX to centered means it And patterns into tumors. of pharmacodynamic those antigens. activation expect human be it’s subset those cells antibodies positive SL-XXXXXX very,

And sure we levels a and agonists, be we biology we therefore, at dose dose has OXXX far it to at think been level our identify so maximized. somewhat can territory explore measure in as OXXX fully the for and I are that we which here want here uncharted as least

Jonathan Miller

Great. much. you sense. Thank Makes very

Operator

question of Needham. comes next line Gil from Our the from Blum

begin. You may

Gil Blum

some to the grade on both escalate, sometimes It the progress. seeing expect that do point immune of dose to all safe. you you looks start low agents? congrats seem But of seeing grade like some immuno-oncology the low at are with be mediated very as And CRS tox, programs the sort rash, level

Taylor Schreiber

Sure. Thanks take for one. the question. this Lini to I’ll ask

Lini Pandite

Yes.

do with given some dose would escalate, What as We that dose dose We’ve lower CDXX that – we milligrams we see through picked degree we to of antibodies and are this talks. kilogram. at expect to the beyond a is kilogram. to to escalation you that As we very CDXX toxicity been well. has encouraged doses, we an especially have are milligrams currently targeted escalate dose-limiting per molecule dose able agonist in X.X X are able the to escalate per

an able saturate us dose as we gives well it to on as so the And opportunity to CDXX, escalate those CDXX both be receptor point occupancy that have receptors. and to

to suddenly the by higher encouraged could be So there that that we’re view dose patients to think a you I doses. this able escalation toxicity I with we fact mean, monitor as at our we’re do. But said, suddenly,

Gil Blum

that XXX, understood clarify on to this And Okay. correctly. I just

So we’re PD-X positive that correct? therapy. discussing enrichment PD-X for patients Is and are refractory following who PD-Xbased

Lini Pandite

correct. correct. That’s that’s Yes,

up patients and at are started efficiently escalation positive. currently get the select for very as really we to to an escalation that reason So the range. the we not are We dose we dose dose low And dose for to possible to range. at that immunologically did that dose who active a wanted point as PD-LX we in now, had

is to no bind plan patients that reason PD-LX. PD-LX is our our And for forward, select moving the with end that molecule one of So positivity.

select to for so actually would sense And make that. it

this. who have of PD-X such PD-LX, are may have acknowledged and certainly agents we therapies, to resistance these patients that other mechanisms that preclude failed Now them as responding from

Gil Blum

today, haven’t an there an going of with FC lot results program, or which digit we one additional makes and a Okay. maybe we’re the here? And Fc the sense. in That a any inactive active been space, whether the chip kind has regarding last following too others, of disclosures ARC’s on discussed much

Taylor Schreiber

There been year. be yet, clinic this next additional any the to disclosure has will around program the not ARC but enter later guidance we providing additional

Gil Blum

our taking for at all definitely And questions. look excellent. forward Okay, SITC. your for results you we Thank

Taylor Schreiber

the questions. for Thanks

Operator

from And from line our of Shu last question the Zhiqiang come will Berenberg.

may begin. You

Zhiqiang Shu

my good Thanks for question. Hi, taking afternoon.

So the is XXX X kilogram. on program, dose your milligram current first per

one of next you kind be I the you the at – that of to… Curious two, times have to level you comfort, guess You what big that, gives can is it three a seems escalate XX, you dose. to junk, more than dose

Taylor Schreiber

Sure. question. Hi to Lini as that one for Zhiqiang, thanks I’ll take ask well. the

Lini Pandite

in escalate We often studies dose and increase. half log this oncologist

a half log So That’s X is reasonable XX that to increase. increase. a

need at now But then very depending And actually to we a reasonable that’s XX, higher not. determine whether we’ll right so we on what see, go or increasing.

Zhiqiang Shu

then And next you combination study, rituximab study a trial? the you for – when the to you’re dose and terms are dose the to at looking when dose X phase of the a with Phase factors in what and of when want combine select as guess combination moving step, it. you select I in gating recommended Got the

Taylor Schreiber

Sure.

for we’re dose, of where what a general, compounds. in dose is find ARC well to targets So which identifying both in of Phase recommended a looking is X see tolerated, saturation we

both expect target will point effects a CDXX patient pharmacodynamic or and the to a pharmacodynamic dose. there that of where And of engagement. every effects same So that the at that a we been has see wherein reached those have continued pharmacodynamic we exact the and that, presumably to And will maximum of mean not plateau, case CDXX CDXX. and XXXXXX after on up saturation, OXXX downstream in see escalation then escalated reach activation

which of all be the for identification probability plateau treat. we maximum there’ll patients improve a maximizes biology so might may dose, selected the And

is and of course looking then mentioned important. the then, as be also this at Of to achieve ensuring of through schedule, PK occupancy not interval. the but system occupancy we free activity in there targets, full the only but is dose And narrowing the sufficient earlier, e drug maintain that the we’ll well in full do observation anti-tumor that should’ve dosing and profile

So collectively studies. are triangulating dose those vectors pick subsequent that into – a we’re our the to going

Zhiqiang Shu

Great. Thanks, Taylor.

Taylor Schreiber

the question. Sure. Thanks for

Operator

of Thank call. Executive have Chief like back of That’s time all the the Q&A I’d turn to Officer over Labs for Shattuck Schreiber, you. At Taylor today’s to we for closing time, call session the remarks. this

Taylor Schreiber

results our financial Shattuck Shattuck, of year. for the and updating conference and business very we remainder all interest updates throughout you much. Labs on thank to quarter appreciate and Thanks operator, look the call. you, joining We forward you in milestones second this continued your Thank

Operator

call. for conference concludes today’s participating. This you Thank

You day. may disconnect. now Have wonderful a

Shattuck Labs (STTK) 14 Aug 212021 Q2 Earnings call transcript